BackgroundIdiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease characterized by unexplained ...
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...
Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...
Researchers have uncovered a critical mechanism behind why certain viral infections, such as COVID-19, lead to lasting lung ...
IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...
A pair of studies presented at the European Respiratory Society Congress 2024 emphasized the importance of close monitoring ...
GlobalData on MSN7d
Boehringer seeks approval for lung fibrosis drug following Phase III winThe Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.
A research group from Ningbo Institute of Materials Technology and Engineering (NIMTE) of the Chinese Academy of Sciences ...
Millions of people in the U.S. are living with lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis and pulmonary arterial hypertension (PAH).
COVID-19 has no impact on body mass index (BMI) trajectory or lung function in people with cystic fibrosis (pwCF) in the year following infection.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback